Valo

Valo Therapeutics Announces €11m Fundraise to Advance Immunotherapy Platform into the Clinic

PRESS RELEASE –Valo Therapeutics Oy (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, announced it has successfully raised Euro 11 million (around $12.75 million US) in an oversubscribed Pre-IPO funding round. Corporate advisory firm Ironside Capital acted as lead manager for Valo Tx. The Pre-IPO fund included participation from …

Valo Therapeutics Announces €11m Fundraise to Advance Immunotherapy Platform into the Clinic Read More »